The French pharmaceutical industry is intensely concerned about the prospective repayment of 2.5 billion French francs ($511.3 million) to the social security system under the reform program set out this month by the Prime Minister, Alain Juppe, which called for a total of 5 billion francs in "economies" from doctors and the pharmaceutical industry (Marketletter November 20).
The government claims that the "exceptional and provisional" contributions by drug companies of the 2.5 billion francs represents the difference between the 3% growth target on general medical treatment spending in 1995 and the actual growth in reimbursable drug spending this year by the health funds of 8.5%.
The funds are expected to reimburse a total of 57 billion francs for drug specialties in 1995, compared with 53.1 billion francs in 1994. This is the first time in the history of the French health service that the drug industry has been required to pay an "exceptional contribution," though the drug wholesale sector has been making such payments since 1991.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze